Compare BIO-TECHNE Corp (TECH) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Information Technology Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Vanguard Information Technology Index Fund ETF trades at $128.27 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 15× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Information Technology Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| TECH | VGT | |
|---|---|---|
Market Cap | $11.36B | $170.20B |
Volume | 5,390,331 | 5,132,883 |
Sector | Health | — |
52-Week High | $72.61 | $129.79 |
52-Week Low | $43.31 | $83.59 |
Typical Hold Time | 63 Days | 129 Days |
Enterprise Value | $11.39B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
VGT trades at $129.37, down 0.32% on the day, with a bullish technical signal driven by moving averages. The ETF recently reached a new 52-week high, reflecting strong momentum in the technology sector. Recent news highlights its historical performance and low expense ratio compared to peers, though RSI levels suggest potential overbought conditions.
The outlook remains positive given the tech sector's growth trajectory and institutional inflows, but risks include concentration in top holdings and sensitivity to AI sector volatility. Long-term investors may benefit from sector exposure, though near-term pullbacks are possible.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
